MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
for the FUROSCIX On-body Infusor to treat pediatric patients weighing 43 kg or more. This expands the treatment's existing reach beyond adults with chronic heart failure/CHF and chronic kidney disease/CKD, providing a home-based option for managing fluid buildup/edema. Earlier on December 1, MannKind Corporation (NASDAQ:MNKD) announced that the US FDA accepted for review a Supplemental NDA for the FUROSCIX ReadyFlow Autoinjector (SCP-111). This device is designed to treat edema in adults suffering from CHF or CKD. The FDA set a Prescription Drug User Fee Act/PDUFA target action date of July 26, 2026, to decide on the application. The ReadyFlow Autoinjector would deliver an IV-equivalent dose of 80 mg/ml subcutaneous furosemide in under 10 seconds. This represents a shift in administration time compared to the currently approved FUROSCIX On-body Infusor, which takes 5 hours to deliver the medication. The On-body Infusor was previously approved for CHF in 2022 and for CKD in 2025. T
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile [Yahoo! Finance]Yahoo! Finance
- MannKind (NASDAQ:MNKD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
- MannKind Provides Business Updates and 2026 Growth Drivers [Yahoo! Finance]Yahoo! Finance
- MannKind (NASDAQ:MNKD) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- MannKind Provides Business Updates and 2026 Growth DriversGlobeNewswire
MNKD
Earnings
- 11/5/25 - Beat
MNKD
Sec Filings
- 1/9/26 - Form 4
- 1/8/26 - Form 144
- 12/29/25 - Form 4
- MNKD's page on the SEC website